Metabolic and inflammatory risk reduction in response to lipid-lowering and lifestyle modification in the medically underserved individuals
Authors:
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 7, 100227
Abstract
No abstract availableKeywords
Funding Information
- Pfizer (R01 HL63895)
- Daiichi-Sankyo (R01 HL63895)
- National Heart, Lung, and Blood Institute (R01 HL63895)
- AstraZeneca (R01 HL63895)
- Abbott Laboratories (R01 HL63895)
- Merck (R01 HL63895)
- Novartis (R01 HL63895)
- National Institutes of Health (R01 HL63895)
- Pfizer Foundation (R01 HL63895)
- Amgen (R01 HL63895)
- Daiichi Sankyo Co Ltd (R01 HL63895)
This publication has 17 references indexed in Scilit:
- Access to Care and Cardiovascular Disease PreventionMedicine, 2015
- Improving Diabetes Care for Minority, Uninsured and Underserved PatientsJournal of Immigrant and Minority Health, 2013
- EFFECT OF RACE AND SOCIOECONOMIC STATUS ON CARDIOVASCULAR RISK FACTOR BURDEN: THE COOPER CENTER LONGITUDINAL STUDY2013
- Reducing cardiovascular disease risk in medically underserved urban and rural communitiesAmerican Heart Journal, 2011
- Health Insurance and Cardiovascular Disease Risk FactorsThe American Journal of Medicine, 2010
- Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studiesBMC Public Health, 2007
- Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: Study design of Carotid Plaque Composition StudyAmerican Heart Journal, 2007
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002
- The influence of outpatient insurance coverage on the microvascular complications of non-insulin-dependent diabetes in Mexican AmericansJournal of Diabetes and its Complications, 1992
- Social inequalities in the decline of coronary mortality.American Journal of Public Health, 1988